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 Abstract 
 Second-generation antipsychotic (SGA) medications intro-
duced about 20  years ago are increasingly used to treat psy-
chiatric illnesses in children and adolescents. There has been 
a fi ve-fold increase in the use of these medications in U.S. 
children and adolescents in the past decade. However, there 
has also been a parallel rise in the incidence of side effects 
associated with these medications, such as obesity, dyslipi-
demia, insulin resistance, and diabetes mellitus. Despite the 
severity of these complications and their fi nancial impact on 
the national healthcare budget, there is neither a clear under-
standing of the mechanisms contributing to these side effects 
nor the best ways to address them. Studies that examined life-
style modifi cation and pharmaceutical agents have yielded 
mixed results. Therefore, clinical studies using agents, such 
as vitamin D, which are inexpensive, readily available, with 
low side effects profi le, and have mechanisms to counter-
act the metabolic side effects of SGA agents, are warranted. 
Vitamin D is a prohormone with skeletal and extraskeletal 
properties that could potentially reduce the severity of these 
metabolic side effects. Its role as an adjunctive therapy for 
the management of metabolic side effects of SGA agents has 
not been adequately studied. Effective strategies to curb these 
side effects will improve the overall health of youths with 
psychiatric illnesses who receive SGAs. Herein we present a 
pilot study on the use of vitamin D in patients on treatment 
with SGAs. 
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 Introduction 
 Second-generation antipsychotic agents and their 
metabolic side effects 
 The atypical or second-generation antipsychotic (SGA) 
agents were introduced approximately two decades ago. 
Their reduced incidence of extrapyramidal side effects and 
reported enhanced therapeutic benefi ts have rapidly led to 
their widespread use in the management of various psychiat-
ric illnesses, such as schizophrenia, schizoaffective disorder, 
and bipolar disorder  (1) . However, results from studies in 
adults with schizophrenia, such as the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE)  (2) , the Cost 
Utility of the Latest Antipsychotic Drugs in Schizophrenia 
Study (CUtLASS)  (3) , and the European First Episode 
Schizophrenia Trial (EuFEST)  (4) , demonstrated rapid 
and signifi cant weight gain in patients treated with these 
medications. 
 There is increasing evidence that SGA agents can increase 
the risk of metabolic abnormalities in patients  (5 – 8) .  Metabolic 
syndrome is a term used to describe the coexistence of obesity, 
hypertension, dyslipidemia, and insulin resistance or diabetes 
in an individual, which confers a high degree of risk for car-
diovascular disease or earlier mortality  (9) . The prevalence of 
metabolic syndrome in patients with chronic schizophrenia is 
37 %  (8) , compared with 24 % in the general population  (10) . 
Patients with schizophrenia also have a three-fold increased 
risk of developing type 2 diabetes when compared with the 
general population  (11) . 
 The Treatment of Early-Onset Schizophrenia Spectrum 
Disorders (TEOSS) study  (12) , an 8-week double-blind 
comparison of fi rst- and second-generation antipsychot-
ics in early onset schizophrenia and schizoaffective disor-
der demonstrated that children who were treated with SGA 
agents had early and signifi cant weight gain, similar to that 
reported for adults. In the TEOSS study, molindone (a fi rst-
generation antipsychotic medication) was compared with 
two SGA agents: olanzapine and risperidone. These two 
SGA agents were not superior to molindone in controlling 
psychiatric symptoms. Moreover, the investigators found 
signifi cant increases in body mass index (BMI) with the SGA 
agents as compared with molindone as shown in Figure  1 A. 
Youths treated with olanzapine gained an average of 6.1  kg 
(SD = 3.6) and increased their BMI by an average of 2.2  kg/m 2 
(SD = 1.2) over the 8-week trial. Subjects treated with risperi-
done gained a mean of 3.7  kg, whereas those on molindone 
showed no mean changes in weight. Furthermore, the olan-
zapine group had greater increases in total cholesterol, low-
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 Figure 1  (A) Comparison of changes in BMI percentiles in children who received molindone as compared with those who received olan-
zapine and risperidone. (B) Comparison of adverse metabolic effect of antipsychotic treatment experienced in subjects with early-onset 
schizophrenia and schizoaffective disorder  (12) . Reprinted with permission form the American Journal of Psychiatry (Copyright © 2008). 
American Psychiatric Association.  
density lipoprotein cholesterol, and insulin levels, relative to 
those in the molindone group (Figure  1 B), suggesting a pro-
pensity for the development of metabolic syndrome. These 
adverse effects raise important public health concerns given 
the expanding use of SGA agents in children and adolescents 
with non-psychotic disorders, such as autism  (12) . 
 The nature of body composition changes of SGA agents 
associated with weight gain in children and adolescents was 
reported by Correll et al.  (13) using bioelectric impedance 
analysis in a study involving 12  weeks of treatment with 
aripiprazole, olanzapine, quetiapine, or risperidone in pedi-
atric patients naive to antipsychotic therapy. They reported 
a weight increase of 8.5  kg with olanzapine, 6.1  kg with 
quetiapine, 5.3  kg with risperidone, and 4.4  kg with aripip-
razole. Each antipsychotic medication was associated with 
signifi cant increase in fat mass and waist circumference. In 
a 6-week randomized, double-blind, placebo-controlled trial 
of olanzapine vs. placebo in adolescents with schizophre-
nia, Kryzhanovskaya et al.  (14) demonstrated a signifi cant 
weight gain in adolescents treated with olanzapine compared 
with placebo (4.3 vs. 0.1  kg, p < 0.001). The weight gain and 
metabolic side effects lead to reduced compliance rates, and 
therefore ineffective treatment of the underlying psychiatric 
illness  (15) . 
 Mechanisms of SGA-induced weight gain and 
metabolic side effects 
 The SGAs act by transiently occupying dopamine D2 recep-
tors in the brain and then rapidly dissociating to allow nor-
mal dopamine transmission  (16) . A controversial theory of 
atypicality proposes that these agents simultaneously block 
5-hydroxytryptamine type 2A (5-HT 2A ) receptors and dop-
amine receptors, thus altering the balance of serotonin and 
dopamine in the brain  (16) . As a result of the brief D2 recep-
tor blockade, these atypical or SGAs are believed to have 
enhanced therapeutic benefi ts and fewer dopamine-related 
side effects than the typical or fi rst-generation antipsychotic 
agents, which have greater affi nity for the D2 binding site 
and are associated with high risk for drug-induced movement 
disorders, such as tardive dyskinesia and other extrapyrami-
dal symptoms  (1, 17) . 
 The precise mechanism of SGA-induced obesity and its 
complications is unclear. Some investigators have suggested 
that this weight gain occurs largely due to an increase in 
appetite  (18) . Fadel et al.  (19) proposed that the propensity 
for weight gain while receiving atypical antipsychotic agents 
was correlated with the degree of  Fos induction in orexin 
neurons of the lateral hypothalamic/perifornical area of 
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rats. Orexins are peptides expressed in neurons of the lateral 
hypothalamus and perifornical area that are potent regula-
tors of feeding and other metabolic processes. Other work-
ers have suggested that because antipsychotic medications 
have a broad range of activity over central neurotransmit-
ter systems, such as serotonin, dopamine, acetylcholine, and 
histamine  (15) , it is possible that their variable antagonistic 
effects on receptor subtypes, such as 5-HT 2A , and histamine 
1 (H 1 ), which are associated with appetite regulation and 
body weight, might lead to hyperphagia and obesity  (20) . 
Studies have shown that antagonism of serotonin, dopamine, 
and norepinephrine receptors may be associated with weight 
gain  (21) , and a robust correlation has been demonstrated 
between SGA medication affi nity for the H 1 receptor and 
antipsychotic-induced weight gain  (22, 23) . Other reports 
have proposed abnormal leptin signaling as a contributor to 
antipsychotic agent-induced weight gain  (24 – 26) . Leptin is 
an adipocyte hormone that regulates food intake and energy 
balance and correlates closely with total body fat mass and 
BMI  (27, 28) . Leptin and insulin decrease appetite by inhib-
iting the production of neuropeptide Y and agouti-related 
protein, while stimulating melanocortin-producing neurons 
in the arcuate nucleus of the hypothalamus. Leptin reduces 
intracellular lipid concentration by decreasing the synthesis 
of fatty acid and triglycerides and by increasing lipid oxida-
tion  (29) . However, studies with adequate statistical power 
and experimental controls have shown no difference in serum 
leptin concentrations and expression when confounding vari-
ables, such as sex and adiposity are taken into account  (30, 
31) . Other data suggest that elevated prolactin contributes to 
SGA agent-induced weight gain by reducing insulin sensi-
tivity or by altering the ratio of androgen to estrogen in the 
body  (32) . 
 An alternative proposed mechanism is a direct action of the 
antipsychotic agents on the pancreatic beta cells. It has been 
suggested that antipsychotic molecules could antagonize the 
muscarinic M3 receptors on beta cells, leading to suppres-
sion of cholinergic-stimulated insulin secretion. This will in 
turn inhibit glucose transport into peripheral tissues leading to 
hyperglycemia  (33) . This SGA agent-induced defi cit in beta-
cell function is believed to be due to a combination of increased 
insulin resistance and decreased glucose-stimulated insulin 
secretion  (34) . Other possible mechanisms include induction 
of peripheral insulin resistance, impairment of beta-cell func-
tion by serotonergic (5-HT 1A/2A/2C ) receptor antagonism, inhi-
bition of beta-cell function via alpha 2-adrenergic receptors, or 
by direct toxic effects on beta cells  (35, 36) . The serotonergic 
receptors, especially the 5-HT 2c receptors, are believed to be 
candidate target receptors for psychotropic-induced weight 
gain, as their antagonism leads to weight gain  (20, 37) . 
 Thus, to date, there is no consensus on the mechanism of 
SGA-mediated weight gain, as all of the above mechanisms 
are speculative. One potential mechanism that has not been 
explored is the role of vitamin D defi ciency in the propaga-
tion of SGA-mediated obesity. This is informed by studies 
suggesting that serum vitamin D concentrations might have 
a direct effect on body weight. Sibley  (38) demonstrated a 
correlation between weight loss and vitamin D levels in an 
11-week study of 38 patients on caloric restriction diets who 
lost 0.196  kg for every 1  ng/mL increase in serum concentra-
tions of 25-hydroxyvitamin D (25-OHD). They also showed 
that higher levels of 25-OHD at baseline predicted increased 
abdominal subcutaneous fat loss. 
 Current modalities of management of SGA-induced 
weight gain and metabolic side effects 
 Various modalities and medications have been proposed 
as adjunctive therapies to attenuate the weight gain associ-
ated with treatment with SGA agents. Studies examining the 
effects of lifestyle interventions and pharmaceutical agents, 
such as sibutramine  (39) , metformin  (40 – 44) , orlistat  (45) , 
amantadine  (46) , and topiramate  (47) have had mixed results. 
Moreover, sibutramine is now unavailable, and the use of 
orlistat is limited by its severe gastrointestinal and systemic 
side effects. Lifestyle interventions, such as psychoeduca-
tional, dietary, and exercise programs can be effective in the 
short term  (48) , but no large-scale study has been performed 
to evaluate long-term effectiveness  (15) , and lifestyle inter-
ventions are diffi cult to sustain, especially for individuals 
with severe psychiatric illness. In general, pharmacologic 
treatment modalities for weight loss are sparse with only a 
few Food and Drug Administration-approved medications. 
Even then, some of these approved medications stimulate 
central serotonin and norepinephrine systems  (49) , a mecha-
nism of action that is opposite to the desired actions of the 
SGA agents. 
 In a randomized, double-blind, placebo-controlled trial, 
Klein et al.  (42) studied the effectiveness of metformin in 
managing weight gain associated with the initiation of SGA 
agents in children and adolescents, ages 10 – 17  years, who 
had gained  > 10 % of body weight during  < 1  year of olan-
zapine, risperidone, or quetiapine therapy. They reported 
the children treated with placebo continued to gain weight 
at a rate of 0.31  kg/week (mean = 4.01  kg, SD = 6.23), over 
16  weeks, despite three family sessions of dietary counsel-
ing. In contrast, the weight of the subjects treated with met-
formin showed little change over the treatment period (mean 
 – 0.13  kg, SD = 2.88). 
 In a 12-week, open-label trial of metformin for the treatment 
of weight gain and metabolic profi les in pediatric patients, 
Shin et al.  (50) studied 11 children and adolescents ages 
10 – 18  years who received metformin orally up to 2000  mg/day. 
They reported no statistically signifi cant reductions in mean 
weight, waist circumference, BMI, serum glucose, and insu-
lin even though 5 of the 11 subjects lost weight. This is in 
contrast to another open-label metformin study by Morrison 
et al.  (40) who studied 19 patients of ages 10 – 18  years for 
12  weeks. In this study, 15 subjects lost weight, 3 gained 
weight, and 1 patient had no weight change. They reported 
a signifi cant decrease in mean weight ( – 2.93  kg, SD = 3.13, 
p = 0.008) and BMI ( – 2.22  kg/m 2 , SD = 1.98, p = 0.003) at 
12  weeks. 
 Although these small studies are promising, there is no 
consensus recommendation supporting the use of metformin 
in the management of weight gain associated with SGA 
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agents. The use of metformin is limited by its gastrointestinal 
side effects, which include stomach upset and nausea; con-
traindication in patients with renal and hepatic dysfunction, 
and concerns regarding its rare but severe side effect of lactic 
acidosis. Therefore, alternative safe and inexpensive agents 
with a high safety profi le that has effi cacy in preventing SGA-
mediated weight gain would be a valuable adjunct to the man-
agement of children with psychiatric disorders requiring SGA 
therapy. 
 Vitamin D 
 General effects of vitamin D 
 Vitamin D is a safe, well-tolerated, and easily available agent 
with no central stimulatory properties. Its primary skeletal 
function is the promotion of calcium absorption from the gut 
and phosphorus reabsorption from the kidneys for the main-
tenance of the skeleton  (51) . Although controversial  (52) , 
there are many reports of extraskeletal effects of vitamin D, 
such as boosting of immune system by modulating B- and 
T-lymphocyte function  (53) , prevention of certain malignan-
cies, such as colon cancer  (54) , the association of a reduction 
in the prevalence of psychiatric illnesses, such as schizophre-
nia in offspring of vitamin D-suffi cient mothers  (55) , and the 
prevention of diabetes mellitus  (56) . 
 Effects of vitamin D on glucose metabolism 
 Normal insulin secretion is partly dependent on 1,25-dihy-
roxyvitamin D (1,25(OH) 2 D 3 ) concentrations in both intact 
animals and isolated islets  (57, 58) . Limited evidence sug-
gests that vitamin D defi ciency increases insulin resistance 
and thus may play a role in the early stages of the develop-
ment of type 2 diabetes  (59) . Low serum vitamin D concen-
trations correlate with impaired glucose tolerance  (60 – 63) , 
whereas administration of supplemental vitamin D to subjects 
with elevated blood glucose levels increases insulin secretion 
 (64, 65) . Similar improvements have been observed in vita-
min D-defi cient subjects following supplementation  (61, 66) . 
Even though there are reports of a correlation between hypo-
vitaminosis D and insulin resistance in obese adolescents 
 (67) , clinical trials with vitamin D supplementation are sparse 
 (59, 65, 68) , especially in patients with psychiatric illnesses 
who receive adipogenic SGA agents. 
 The circulating concentration of 25-OHD is regarded 
as the best index of nutritional vitamin D status. There are 
differing defi nitions for suboptimal serum concentration of 
25-OHD  (51) . In general, hypovitaminosis D is defi ned as 
serum 25-OHD concentrations  < 75  mmol/L (31.25  ng/mL), 
and vitamin D defi ciency as serum 25-OHD concentration 
 < 50  nmol/L (20.8  ng/mL)  (67) . 
 Vitamin D defi ciency has been reported in obese individuals 
 (69 – 72) , although the etiology is unclear. Proposed causative 
factors include poor general nutrition, which results from low 
intake of vitamin D-containing foods, such as salmon, inad-
equate exposure to sunlight, and the sequestration of vitamin 
D in fat stores in obese individuals, which makes the vitamin 
D unavailable for biological activities  (70) . 
 It is possible that vitamin D defi ciency acts synergistically 
with other pathways to propagate the weight gain associ-
ated with SGA agents. Although a direct catabolic effect on 
vitamin D molecule by SGA agents has not been demon-
strated, certain drugs directly impair vitamin D metabolism 
and reduce its levels. Pascussi et al.  (73) conducted both in 
vivo (using human hepatocytes) and in vitro (in mice) experi-
ments showing that antiepileptic drugs that activate pregnane 
X receptor (PXR) enhance CYP24 expression and accelerate 
the catabolism of 25-OHD, leading to vitamin D defi ciency. 
Similarly, xenobiotic drugs, including rifampin, glucocorti-
coids, and antiretroviral drugs, may induce vitamin D defi -
ciency through the same pathway  (74) . It is likely that other 
families of drugs also are activators of PXR and may increase 
vitamin D catabolism  (74) in the liver, leading to vitamin D 
defi ciency and osteomalacia  (73, 75) . Interestingly, treatment 
with SGA agents has also been associated with both vitamin 
D defi ciency and osteomalacia  (76, 77) . Given the above 
fi ndings, it is possible that SGA agents might activate PXR 
and induce vitamin D defi ciency, which in turn results in 
weight accrual. 
 Central and peripheral mechanisms of the antiobesity 
effects of vitamin D 
 Peripheral mechanism  Vitamin D defi ciency is marked by 
low serum 25-OHD and elevated parathyroid hormone (PTH) 
and 1,25(OH) 2 D 3  (70 – 72, 78) to maintain normocalcemia. 
This compensatory increase in 1,25(OH) 2 D 3 level is the 
principal proposed mechanism of vitamin D defi ciency-related 
adipogenesis. Elevated serum concentrations of 1,25(OH) 2 D 3 
are believed to promote obesity by binding to a membrane 
vitamin D receptor called the membrane-associated rapid 
response to steroid receptor  (79, 80) and inducing a rapid 
infl ux of calcium ions into adipocytes (Figure  2 ). Intracellular 
Ca 2 +  , a key regulator of adipocyte lipid metabolism, stimulates 
the expression and activity of fatty acid synthase (FAS), a key 
enzyme for  de novo lipogenesis, while inhibiting basal and 
agonist-stimulated lipolysis in adipocytes  (81) . This results in 
increased lipid accumulation in adipocytes  (82) and attendant 
obesity, which leads to a further decrease in 25-OHD as a result 
of sequestration of vitamin D in fat depots. This establishes a 
vicious cycle of worsening obesity and vitamin D defi ciency. 
 Therefore, pharmacologic interventions aimed at normaliz-
ing serum concentrations of 25-OHD may prevent both PTH 
elevation and compensatory activation of 25-OHD to 1, 25 
(OH) 2 D 3 , which in turn will preclude the elevation of intrac-
ellular calcium ion concentrations and consequently reduces 
the activity of FAS. This breaks the vicious cycle of obesity 
and vitamin D defi ciency. 
 Central mechanism  FAS activity is present peripherally 
in adipocytes and centrally in the hypothalamus  (81, 83) . 
Hypothalamic fatty acid metabolism plays a major role in 
the modulation of energy balance, affecting both feeding and 
energy expenditure  (84) . Treatments with FAS inhibitors, such 
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as cerulenin, or drugs that down-regulate FAS expression, 
such as tamoxifen, induce remarkable weight loss and 
hypophagia  (85) . The anorectic effect of these drugs requires 
the accumulation of malonyl-CoA in the hypothalamus, which 
may serve as a signal of nutrient abundance by critical neurons 
regulating food intake  (84) , decreased expression of orexigenic 
(agouti-related protein, neuropeptide Y), and elevated 
expression of anorexigenic (cocaine- and amphetamine-
regulated transcript, proopiomelanocortin) neuropeptides in 
the arcuate nucleus  (86, 87) . It is possible, therefore, to induce 
similar effects as drugs that down-regulate FAS activity by 
preventing the up-regulation of FAS through optimal vitamin 
D supplementation. One study demonstrated a correlation 
between weight loss and vitamin D levels in adults receiving 
caloric restriction diets who lost 0.196  kg for every 1 ng/mL 
increase in serum concentrations of 25-OHD  (38) . 
 A feasibility study on the role of vitamin D in patients 
receiving SGAs 
 Given the paucity of data on the role of vitamin D supplemen-
tation in children and adolescents with SGA-induced obesity, 
we designed a feasibility study to evaluate the relationship 
between changes in anthropometry and serum concentrations 
of 25-OHD in overweight and obese patients on treatment 
with SGA agents. Our primary objective was to establish the 
feasibility of enrolling adolescents with major psychiatric dis-
orders in an in-patient setting in a treatment study. Our second-
ary aim was to conduct an open-label pilot study to determine 
the safety profi le and effi cacy of supplemental vitamin D in 
psychiatric patients receiving SGA medications. We believed 
that the results of such a study would form the framework for 
the development of a longer-term clinical study. 
 All subjects had a  Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition  (88) Axis 1 diagnosis and 
had been receiving treatment with SGA medication for more 
than 3  months. All had a BMI of  > 85th percentile and had 
a 25-hydroxyvitamin D level of  < 75  nmol/L (30  ng/mL). 
Subjects were excluded from participation if they met the cri-
teria for an eating disorder, substance abuse/dependence, sig-
nifi cant medical or neurological illness, IQ  < 70, pregnancy, 
recent history of suicidality, or being psychiatrically unstable 
on their current medication regimen. The study was approved 
by the University of Massachusetts Medical School and the 
Department of Mental Health Services Institutional Review 
Boards. Signed parental informed consent with signed assent 
of the youth were obtained before study enrollment and base-
line eligibility assessment. 
 All participants were residents of a chronic care facility for 
adolescents with psychiatric disorders. All received 10 drops 
(2000 IU) of ergocalciferol every morning before breakfast 
for 8  weeks. Anthropometric measures, height (cm), weight 
(kg), BMI (kg/m 2 ), as well as laboratory evaluations were 
performed in the fasting state. 
 Of the 12 participants, 4 were males and 8 were females. 
Of these, eight were white, two were Hispanic, and two were 
African American. All participants completed the study. The 
average age was 16.6 ± 1.65  years, with a range of 13 – 18  years. 
At the end of the study, there was a non-signifi cant decrease in 
body weight standard deviation score from baseline to the end 
Inhibit lipolysis
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synthase 
de novo lipogenesis 
[Ca2+]i
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1,25(OH)2D3
A
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+
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 Figure 2  In vitamin D-defi cient states, PTH accelerates the conversion of 25-OHD to 1,25(OH) 2 D 3 , which results in a compensatory increase 
in serum 1,25-dihydroxyvitamin D level, which drives the infl ux of calcium ions into the cell and consequent activation of FAS. Adapted from 
Zemel  (81) . 
AUTHOR’S COPY | AUTORENEXEMPLAR 
AUTHOR’S COPY | AUTORENEXEMPLAR 
624  Nwosu et al.: Potential role for adjunctive vitamin D therapy
of study, 2.56 ± 1.32 vs. 2.49 ± 1.38 (p = 0.18) (95 % confi dence 
interval  – 0.200 to  0.058). One subject experienced no change 
in weight, fi ve subjects gained weight, and six subjects lost 
weight. When analyzed by sex, two males gained weight, one 
lost weight, and one had no weight change. Three females 
gained weight, whereas fi ve lost weight. Serum concentra-
tions of 25-OHD increased signifi cantly from baseline to the 
end of study 46.5 ± 18.65 vs. 72.75 ± 21.12  nmol/L (18.6 ± 7.46 
vs. 29.1 ± 8.45  ng/mL) (p = 0.0001). There were no side effects 
from the vitamin D supplementation. Thus, we achieved our 
primary objective, which was to establish the feasibility of 
enrolling adolescents with major psychiatric disorders in an 
in-patient setting in a treatment study. We also demonstrated 
that adjunctive vitamin D supplementation is safe in psychi-
atric patients receiving SGA medications. We did not design 
the study with suffi cient power or long enough duration to 
detect signifi cant changes in weight or BMI, as this was a 
feasibility study. We are now planning a trial of longer dura-
tion with vitamin D supplementation, which is inexpensive, 
readily available, with a low side effect profi le, which could 
counteract the metabolic side effects of SGA agents. 
 Summary and conclusion 
 In summary, SGA medications are increasingly being pre-
scribed to treat psychiatric illnesses in children and adoles-
cents. However, the use of these agents is limited by their 
severe metabolic side effects. The mechanism(s) of these 
adverse events are unknown, and there is a lack of consensus 
on the best approach to address these problems. In conclusion, 
adjunctive vitamin D therapy may play a role in counteracting 
the adipogenic effects of SGA agents. 
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